Athira Pharma Inc. (NASDAQ: ATHA) Stock Information | RedChip

Athira Pharma Inc. (NASDAQ: ATHA)


$0.5399
-0.0081 ( -1.03% ) 119.0K

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Market Data


Open


$0.5399

Previous close


$0.5480

Volume


119.0K

Market cap


$20.71M

Day range


$0.5290 - $0.5430

52 week range


$0.4115 - $4.2984

SEC Filings


Form Type Description Pages Date
8-k 8K-related 13 May 17, 2024
10-q Quarterly Reports 66 May 15, 2024
8-k 8K-related 13 May 15, 2024
3 Insider transactions 1 Apr 16, 2024
4 Insider transactions 1 Apr 16, 2024
def Proxies and info statements 27 Apr 09, 2024
ars Annual reports 1 Apr 09, 2024
pre Proxies and info statements 26 Mar 28, 2024
10-k Annual reports 99 Feb 22, 2024
8-k 8K-related 15 Feb 22, 2024

Latest News